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Background: Epithelial ovarian cancer (EOC) is a significant cause of morbidity and mortality. MicroRNAs play
important roles in cancer development and progression. The microRNA miR-211 is localized on intron 6 of the
Trpm1 gene at 15q13-q14, a locus that is frequently lost in neoplasms. Its function and loss-of-function have been
described in normal and cancer cells and tissues. miR-211 is known to be dysregulated in ovarian cancer: however,
its function and the downstream effect of its loss-of-function in ovarian cancer have not been described before.
Methods: We analyzed miR-211 expression in clinical samples of primary EOC tissues compared to normal epithelial
ovarian tissues and in the EOC cell lines: OVCAR3, Caov3, OVCA429, SKOV3 and A2780 compared to human ovarian
surface epithelial cells. We then investigated the effect of miR-211 on EOC cell proliferation and apoptosis by counting
cell numbers, MTT, colony formation, cell cycle, and PI/Annexin V staining assays. A luciferase reporter system was
developed to assess miR-211 regulation of the predicted targets. Expression level of discovered targets and correlation
with miR-211 expression were analyzed in EOC tissues. Finally, OVCAR3 stably expressing miR-211 or control cells were
injected subcutaneously into mice to determine in vivo effect of miR-211 on tumorigenesis.
Results: We found that the expression of miR-211 is downregulated in EOC tissues and cell lines compared to normal
epithelial ovarian tissue and human ovarian surface epithelial cells, respectively. miR-211 was found to arrest cells in the
G0/G1-phase, inhibit proliferation and induce apoptosis. Cyclin D1 and CDK6 were found to be direct targets of
miR-211, and when overexpressed in miR-211-expressing EOC cells, could restore proliferative ability. Finally,
in vitro investigation confirmed that miR-211 is a tumor suppressor that controls Cyclin D1 and CDK6 expression.
Conclusions: Our results demonstrate that miR-211 is a tumor suppressor that controls expression of Cyclin D1
and CDK6, and that its downregulation results in overexpression of Cyclin D1 and CDK6 which increases proliferation
ability of EOC cells to proliferate compared to normal cells.
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Ovarian cancer (OC) has a high mortality rate and low
5-year survival rate due to lack of early, safe and non-
invasive detection methods. This malignancy also de-
velops chemoresistance during recurrence after initial
chemotherapy [1-4]. Therefore, new therapies, clinical
biomarkers and treatment targets are in demand.
MicroRNAs (miRNAs) regulate gene expression at the
post-transcriptional level [5-7] and miRNA dysregulation* Correspondence: lougehyd@163.com
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unless otherwise stated.is frequently associated with cancer progression, includ-
ing OC [8-12]. The microRNA miR-211 is localized on
intron 6 of the Trpm1 gene at 15q13-q14, a locus that is
frequently lost in neoplasms [13-16]. MiR-211 functions
and the effect of loss-of-function have been described in
normal and cancer cells and tissues. Using mouse
embryonic fibroblasts, Chitnis et al. [17] found that
miR-211 is a pro-survival molecule that is expressed in a
PERK (aka EIF2AK3, Eukaryotic translation initiation
factor 2-alpha kinase) -dependent manner and regulates
the expression of chop/gadd153 by mediating temporal
accumulation of the pro-apoptotic transcription factors is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mal cells in response to stress [18-22] and Chitnis et al.
[17] suggested that miR-211 negatively regulates chop
accumulation, allowing cells to re-establish homeostasis
before having to commit to apoptosis.
In clinical melanoma samples, Mazar et al. [8] found
that miR-211 targets KCNMA1, is downregulated in
melanoma and that its expression is microphthalma-
associated transcription factor dependent. This tran-
scription factor is important for melanocyte growth,
maturation, apoptosis and pigmentation [23]. Bell et al.
found that miR-211 contributes to melanoma adhesion
by targeting the AMP-activated protein kinase-related
kinase NUAKI and that inhibition of miR-211 resulted
in increased NUAK1 expression and reduced adhesion
[24]. In glioblastoma multiform, miR-211 was found
to be downregulated with an inverse correlation of
miR-211 expression and matrix metalloproteinase-9
expression [25]. The authors suggested that rescuing
miR-211 expression could have therapeutic applications.
Conversely, others reported that in oral carcinoma, miR-
211 is upregulated, contributes to progression of oral
carcinoma and correlates with poor prognosis in oral
carcinoma [26].
The present study investigated the regulatory role and
implications of aberrant expression of miR-211 in
epithelial OC (EOC). We report that miR-211 is down-
regulated in EOC, inhibits proliferation and induces
apoptosis in EOC cells in vitro and that overexpression
of miR-211 inhibits growth of EOC xenograft tumors
in vivo by repressing Cyclin D1 and CDK6 expression.
Results
miR-211 is downregulated in EOC tissues and cell lines
Searching the literature, we found that miR-211 is down-
regulated in OC tissues [9]. We further used a publicFigure 1 miR-211 is downregulated in epithelial ovarian cancer (EOC)
ovarian carcinomas (CCOC, n = 9) and high-grade serous ovarian carcinomas (
(GSE47841, p < 0.001). B. Levels of miR-211 were lower in 60 EOC tissues com
miRNA expression normalized to U6 snRNA was determined by setting the m
expression was downregulated in six EOC cell lines (OVCAR3, Caov3, OVCA4
epithelial (HOSE) cells. Relative levels of miRNA expression normalized to U6
HOSE cells to 1. *p < 0.05, **p < 0.01. Data are presented as mean ± SEM ofdata base to investigate miR-211 expression in EOC tis-
sues and found that the of miR-211 expression was sig-
nificantly lower in clear-cell OC (CCOC, n = 9) and
high-grade serous ovarian carcinomas (HGSC, n = 12)
than in ovarian surface epithelial cells (OSES, n = 9)
(Figure 1A, GSE47841, p < 0.001) [27]. Next, we ex-
plored this finding in clinical samples by comparing
miR-211 expression in normal epithelial ovarian tissues
with primary EOC tissues. Consistent with the men-
tioned literature, miR-211 expression was significantly
lower in EOC tissues than in normal epithelial ovarian
tissues (Figure 1B, p < 0.01). We extended our investiga-
tions to six EOC cell lines (OVCAR3, Caov3, OVCA429,
SKOV3, A2780 and COV644) and found that their
miR-211 expression levels were significantly lower
than those of human ovarian surface epithelial (HOSE)
cells (Figure 1C). These findings suggest that downregula-
tion of miR-221 may affect EOC development.
miR-211 inhibits proliferation and induces apoptosis of
EOC cells
To investigate the function of miR-211 in EOC
tumorigenesis, we transfected miR-211 or miR-Ctrl in
OVCAR3 and SKOV3 cell lines and determined their
miR-211 levels 48 hours after transfection. Results
showed increased miR-211 levels in both miR-211 trans-
fected cell lines compared to miR-Ctrl transfected cells
(Figure 2A). We then investigated the effect of miR-211
on OVCAR3 and SKOV3 cell proliferation. As shown in
Figure 2B, miR-211 significantly inhibited EOC prolifera-
tion. MTT assay further confirmed that miR-211 had a
negative effect on EOC cell proliferation (Figure 2C). To
examine the effect of miR-211 on long-term EOC cell
proliferation, we performed colony formation assays. We
first constructed a miR-211 lentiviral vector (LV-miR-211),
then infected OVCAR3 and SKOV3 cells with LV-miR-211tissues and cell lines. A. Expression of miR-211 was lower in clear cell
HGSC, n = 12) compared to ovarian surface epithelial cells (OSEC, n = 9)
pared to 20 normal epithelial tissues samples. **p < 0.01. Relative levels of
iRNA expression levels of normal epithelial tissue samples to 1. C. miR-211
29, SKOV3, A2780 and COV644) compared to human ovarian surface
snRNA was determined by setting the miRNA expression levels of
three independent experiments.
Figure 2 miR-211 inhibits EOC cell proliferation. A. miR-211 levels in OVCAR3 and SKOV3 cells transfected with miR-211 or miR-Ctrl. B. OVCAR3
and SKOV3 cells were transfected with miR-211 or miR-Ctrl for 48 hours, then seeded in 24-well plates (0.25 × 104 cells/well). Viable cell numbers
were counted at indicated time points. C. MTT assay of OVCAR3 and SKOV3 cells transfected with miR-211 or miR-Ctrl. D. Expression of miR-211
in LV-miR-211 or LV-miR-Ctrl transfected OVCAR3 and SKOV3 cells. E. Colony formation assay in OVCAR3 and SKOV3 cells stably expressing
miR-211 compared to control cells. *p < 0.05, **p < 0.01 compared to miR-Ctrl or LV-miR-Ctrl transfected cells. Data are presented as mean ± SEM of
three independent experiments.
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LV-miR-211 and LV-miR-Ctrl cells were subjected to col-
ony formation assay for two weeks. As expected, miR-211
significantly reduced colony numbers to 20% in both EOC
cell lines (Figure 2E).
Next, we performed cell cycle analysis and noted that
miR-211 transfection significantly arrested significantly
more cells in the G0/G1 phase (Figure 3A) than miR-
211-Ctrl transfection. To investigate whether miR-211
affects EOC cell apoptosis, OVCAR3 and SKOV3 cells
were transfected with miR-211 and apoptosis assessed
48 hours later. As shown in Figure 3B, miR-211 trans-
fected cells had a higher incidence of apoptosis than
miR-211-Ctrl transfected cells. These results suggest that
miR-211 inhibits EOC cell proliferation and induces
apoptosis.
Cyclin D1 and CDK6 are direct target of miR-211
We used microRNA.org, Targetscan and miRWalk data-
bases to predict potential miR-211 targets. Hundreds of
potential targets were found, but we selected transcrip-
tion factor 4 (TCF4), Cyclin D1, Cyclin D2, Cyclin D3
and Cyclin dependent kinase 6 (CDK6) for further ana-
lysis since these genes have previously been reported toFigure 3 miR-211 arrests EOC cell cycle and induces apoptosis. A. Cel
miR-Ctrl. B. Apoptosis analysis of OVCAR3 and SKOV3 cells transfected with miR
cells. Data are presented as mean ± SEM of three independent experiments.affect EOC cell proliferation [28-31] (Figure 4A). We
inserted TCF4, CDK6, Cyclin D1, Cyclin D2 and Cyclin
D3 3′UTR into luciferase reporter vectors and co-
transfected with miR-211 expression plasmid into
OVCAR3 and SKOV3 cells (Figure 4A). Forty-eight
hours after transfection, only cells transfected with
CDK6 and Cyclin D1 3′UTR plasmids had lower lucifer-
ase activity than their controls. Luciferase activity in
both of these cell lines was 70% less than that of the
miR-Ctrl groups (Figure 4B). Next, we compared the 3′
UTR sequence of Cyclin D1 and CDK6 with miR-211.
Both genes have two potential complementary miR-211
binding sites (Figure 4C, D). We next constructed Cyclin
D1 and CDK6 3′UTR mutant plasmid (Additional file 1:
Figure S1A-B), cotransfected with miR-211 and then
performed luciferase assay. The data revealed that miR-
211 targets two sites in Cyclin D1 and CDK6 (Additional
file 1: Figure S1C-D). To confirm that Cyclin D1 and
CDK6 are specifically targeted by miR-211, OVCAR3
and SKOV3 cells transfected with miR-211 or infected
with LV-miR-211 were subjected to western blot ana-
lysis. We found that the protein levels of Cyclin D1 and
CDK6 were lower in miR-211 and LV-miR-211 trans-
fected cells compared to control (Figure 4E, F). Thel cycle assay of OVCAR3 and SKOV3 cells transfected with miR-211 or
-Ctrl or miR-211. *p < 0.05, **p < 0.01 compared to miR-Ctrl transfected
Figure 4 Cyclin D1 and CDK6 are miR-211 targets. A. Schematic representation showing the five predicted miR-211 targets (TCF4, Cyclin D1,
Cyclin D2, Cyclin D3 and CDK6) screened using three algorithms (miRNA.org, miRWalk and Targetscan). B. OVCAR3 cells were co-transfected with
TCF4, CDK6, Cyclin D1, Cyclin D2 or Cyclin D3 3′UTR pGL plasmid with miR-211. Forty-eight hours later, luciferase assay was performed. *p < 0.05
compared to miR-Ctrl transfected cells. Data are presented as mean ± SEM of three independent experiments. C-D. Sequence of miR-211 with the
putative binding sites of Cyclin D1 (C) and CDK6 (D) 3′ UTR. E. Western blot of Cyclin D1 and CDK6 levels in OVCAR3 and SKOV3 cells transfected
with miR-211 or miR-Ctrl. F. Western blot of Cyclin D1 and CDK6 levels in OVCAR3 and SKOV3 cells transfected with LV-miR-211 or LV-miR-Ctrl.
G-H. The mRNA expression levels of Cyclin D1 (G) or CDK6 (H) correlated inversely with miR-211. I-J. Cyclin D1 (I) and CDK6 (J) expression in
ovarian tissues (GDS3592/Cyclin D1, n = 24, p = 0.017; GDS3592/CDK6, n = 24, p = 0.016).
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miR-211 were measured in 60 EOC tissues using qRT-
PCR to analyze their correlation. Spearman correlation
analysis revealed a reverse correlation between miR-211
expression and Cyclin D1 or miR-211 and CDK6 expres-
sion (Figure 4G, H). The high expression of Cyclin D1
and CDK6 in OEC tissues compared to normal tissue
was consistent with results from the public database
(Figure 4I, J) [32]. Taken together, these results indicate
that miR-211 can repress the expression of Cyclin D1
and CDK6 in EOC by directly targeting the 3′UTR of
Cyclin D1 and CDK6 mRNA.
miR-211 affects ovarian cell proliferation and apoptosis
through suppression of Cyclin D1 and CDK6
Our previous data suggests that miR-211 inhibits EOC
cell proliferation and that Cyclin D1 and CDK6 are dir-
ect targets of miR-211. To demonstrate that miR-211
regulates cell proliferation through Cyclin D1 and
CDK6, we tested whether Cyclin D1 and CDK6 could
rescue the impaired proliferative phenotype in miR-211
overexpressing OVCAR3 and SKOV3 cells. Western
blot was performed to examine Cyclin D1 and CDK6
levels in cells transfected with LV-miR-Ctrl, LV-miR-211,
LV-miR-211 + Cyclin D1 and LV-miR-211 + CDK6
(Figure 5A). Cell counting and MTT assay were per-
formed to analyze cell proliferation. The results indicate
that miR-211 inhibited proliferation, while Cyclin D1 or
CDK6 partly, and Cyclin D1 + CDK6 almost completely
restored cell proliferation (Figure 5B-F). Furthermore, we
performed cell cycle assays and found that Cyclin D1 or
CDK6 partly rescued the cell proliferation that had been
inhibited by miR-211 (Figure 6A). MiR-211 overexpres-
sion led to more cell apoptosis, while Cyclin D1 and
CDK6 each significantly reduced apoptosis (Figure 6B).
When we overexpressed Cyclin D1 and CDK6 in miR-
211-overexpressing cells, miR-211-induced cell cycle ar-
rest and apoptosis were completely abrogated (Figure 6C
and D). These results together demonstrate that miR-211
affects EOC cell proliferation, at least in part, through
suppression of Cyclin D1 and CDK6.
miR-211 reduces EOC tumorigenesis in vivo
We performed in vivo experiments to confirm our
in vitro results that suggested that miR-211 inhibited
EOC cell proliferation by targeting Cyclin D1 and
CDK6. Sixteen mice were randomly divided into two
groups. OVCAR3 cells stably expressing miR-211 or
control cells were injected subcutaneously into mice in
each group. We found that tumor growth was slower in
the LV-miR-211 group compared to the LV-miR-Ctrl
group (Figure 7A). The tumor weights and sizes were
smaller in LV-miR-211 group compared to LV-miR-Ctrl
group (Figure 7B, C). Finally, these tumor tissues wereassessed with immunohistochemistry. We observed that
Cyclin D1 and CDK6 staining in LV-miR-211 group
was weaker than in the control group (Figure 7D).
These in vivo results further indicated that miR-211
inhibits EOC growth and reduces Cyclin D1 and CDK6
expression.
Discussion
MiRNAs are undoubtedly pivotal to tumorigenesis and
understanding their functions may help provide new
cancer therapies [33-36]. In the present study, we per-
formed a database search for miR-211 expression in hu-
man ovarian cancer tissues compared to healthy control
tissue, and found that miR-211 was significantly down-
regulated in clear-cell and high-grade serous carcinomas.
This was further confirmed in clinical primary EOC
samples and in EOC cell lines.
We further investigated the significance of miR-211
expression in EOC in vitro and found that miR-211 sig-
nificantly modulated EOC cell proliferation and colony
formation. Cell cycle analysis showed that miR-211
arrested cells in the G0/G1 phase, resulting in apoptosis.
Using bioinformatics, we identified several miR-211 tar-
gets and confirmed with luciferase assay that miR-211
directly binds to sequences in Cyclin D1 and CDK6
mRNA, repressing their translation into protein. Further
in vitro investigations showed that miR-211 affected
EOC cell proliferation and apoptosis through suppress-
ing the expression of Cyclin D1 and CDK6.
We confirmed our in vitro observations in vivo with a
mouse tumor model. As expected, we found that Cyclin
D1 and CDK6 were downregulated in vivo by miR-211
and that EOC tumor growth was reduced significantly
by miR-211 overexpression.
Dysregulated expression of CDK6 and Cyclin D1 has
been reported in several cancers, including head and
neck squamous cell carcinoma, non-small cell lung
carcinoma, endometrial cancer, melanoma, pancreatic
cancer, breast cancer, colorectal cancer, mantle cell
lymphoma, multiple myeloma, prostate cancer, endo-
metrial cancer and oesophageal cancer (Cyclin D1, [37]),
and glioblastoma, myxofibrosarcoma, lymphoid malig-
nancies and Ewing’s sarcoma cell line (CDK6, [38-42]).
We did not investigate the effect of dysregulated
CDK6 and Cyclin D1 on downstream gene expression;
however, both have been ascribed several functions. Cyc-
lin D1 controls CDK6 activity and is known to affect
angiogenesis, respond to growth factor stimulation and
stimulates G1 progression. Overexpression of Cyclin D1
(and other Cyclins) was found to shorten the G1-phase
of the cell cycle in various cell types [43-45] and inhibit-
ing Cyclin D1 in human fibroblasts was found to inhibit
progression through G1 [45,46], which is consistent
with our observations in EOC. Also, D-type Cyclin
Figure 5 (See legend on next page.)
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Figure 5 miR-211 affects EOC cell proliferation through suppression of Cyclin D1 and CDK6. A. Western blot of Cyclin D1 and CDK6 levels
in OVCAR3 and SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211, LV-miR-211 + Cyclin D1 or LV-miR-211 + CDK6 plasmids. B. Cell counting
of OVCAR3 and SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211, LV-miR-211 + Cyclin D1 or LV-miR-211 + CDK6 plasmids. C. MTT assay of
OVCAR3 and SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211, LV-miR-211 + Cyclin D1 or LV-miR-211 + CDK6 plasmids. D. Western blot of
Cyclin D1 and CDK6 levels in OVCAR3 and SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211 or LV-miR-211 + Cyclin D1 + CDK6 plasmids.
E. Cell counting of OVCAR3 and SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211 or LV-miR-211 + Cyclin D1 + CDK6 plasmids. F. MTT
assay in OVCAR3 and SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211 or LV-miR-211 + Cyclin D1 + CDK6 plasmids. *p < 0.05 compared
to LV-miR-Ctrl transfected cells. Data are presented as mean ± SEM of three independent experiments.
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caused by retinoblastoma tumor suppressor protein (Rb)
in Saos-2 osteosarcoma cells [47,48]. Although Cyclin D1
interacts with CDK6 to exert many of its functions, it
also performs CDK6-independent functions such as:
transcriptional regulation leading to cell growth, tissue-
specific differentiation and cell cycle progression, as well
as chromatin modifications and interaction with nuclear
hormone receptors which both lead to differentiation
and androgen-receptor-dependent cell cycle progression
(reviewed by [37]).
CDK6 is a kinase catalytic subunit of a protein kinase
complex that is involved in G1 progression and G1/S
transition. CDK6 activity first occurs in mid G1-phase, is
controlled by D-type Cyclins (i.e. Cyclin D1) and INK4
family members, and regulates Rb activity by phosphor-
ylation [49]. Phosphorylation of Rb leads to the release
of E2fs, which then activate transcription of genes re-
quired for S-phase entry [50]. Very recently, Handschick
et al. [51] reported that CDK6 is a co-factor of NF-κB
that interacts physically with the NF-κB subunit p65
and is found at promoters of NF-κB target genes.
Thus, dysregulated CDK6 and Cyclin D1 expression is
significant as it is likely to affect expression of S-phase
entry proteins, and the cytokine and chemokine ex-
pression profile of EOC, contributing to oncogenesis
and tumorigenesis.
CDK6 overexpression increases cell proliferation and
reduces DNA repair activity by accelerating G1/S -phase
progression. In glioma, CDK6 knockdown was found to
increase sensitivity to chemotherapy [52]. On this basis,
it is possible that miR-211-mediated inhibition of CDK6
expression in EOC could be a useful epigenetic thera-
peutic approach, although further experiments would be
required to determine this.
In summary, we found that miR-211 negatively regu-
lates CDK6 and Cyclin D1 activity and that miR-211 is
downregulated in EOC, leading to aberrant expression
of CDK6 and Cyclin D1, which results in loss of cell
cycle control. Cyclin D1 and CDK6 appear to be key
players in EOC tumorigenesis, and our discovery of cor-
related expression of miR-211 and CDK6/Cyclin D1 pro-
vides new insight that presents tentative methods for
diagnosis, prognosis and therapy for EOC, and a rationalfor further investigation into the potential use of miR-
211 for diagnosis and therapy.
Materials and methods
Human samples
This study was approved by the Medical Ethics Committee
of Harbin Medical University Cancer Hospital and all pa-
tients provided informed consent. Tissues were collected
from patients who underwent surgery at the Department
of Obstetrics and Gynecology of Harbin Medical
University Cancer Hospital between 2012 and 2013,
including 60 epithelial EOC tissues and 20 normal
epithelial ovarian tissue sections. Patients with previous
radiation therapy, chemotherapy, or immunotherapy,
were excluded from the study. The histopathological
diagnostics was performed according to the World
Health Organization criteria. All fresh specimens were
stored at −80°C for further use. Patients’ characteristics
including presenting age, clinical stage, pathological stage
and tumor size are available in Table 1.
Cancer cell lines and primary normal epithelial cells
The human EOC cell lines (OVCAR3, Caov3, OVCA429,
SKOV3 and A2780) and normal Human Ovarian Surface
Epithelial (HOSE) cells were acquired from the China
Center for Type Culture Collection (CCTCC). The
COV644 cell line was purchased from Sigma (St. Louis,
MO). EOC cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Gibco-BRL, Gaithersburg, MD)
supplemented with 10% fetal bovine serum and antibiotics
(Gibco). HOSE cells were cultured in medium containing
1:1 mixture of MCDB 105 and M199 medium (Sigma). All
cells were incubated at 37°C in a humidified atmosphere
containing 5% CO2.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using Trizol reagent (Invitro-
gen, Carlsbad, CA). To quantitate miR-211 expression,
total RNA was polyadenylated and reverse transcribed
using the TaqMan MicroRNA Reverse Transcription Kit
and TaqMan miRNA assay (Applied Biosystems, Foster
City, CA), according to the manufacturer’s instructions.
U6 small nuclear RNA was used as the internal control.
qRT-PCR analyses for mRNA of Cyclin D1 and CDK6
Figure 6 (See legend on next page.)
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Figure 6 miR-211 regulates EOC cell cycle and cell apoptosis via repression of Cyclin D1 and CDK6. A. Cell cycle assay of OVCAR3 and
SKOV3 cells tranfected with LV-miR-Ctrl, LV-miR-211, LV-miR-211 + Cyclin D1 or LV-miR-211 + CDK6 plasmids. B. Apoptosis analysis of OVCAR3 and
SKOV3 cells transfected with LV-miR-Ctrl, LV-miR-211, LV-miR-211 + Cyclin D1 or LV-miR-211 + CDK6 plasmids. C. Cell cycle assay of OVCAR3 and
SKOV3 cells tranfected with LV-miR-Ctrl, LV-miR-211 or LV-miR-211 + Cyclin D1 + CDK6 plasmids. D. Apoptosis analysis of OVCAR3 and SKOV3 cells
transfected with LV-miR-Ctrl, LV-miR-211 or LV-miR-211 + Cyclin D1 + CDK6 plasmids. *p < 0.05, **p < 0.01 compared to LV-miR-Ctrl transfected
cells. Data are presented as mean ± SEM of three independent experiments.
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(Qiagen, Valencia, CA). The mRNA level of β-actin was
measured as an internal control. RT-PCR was performed
in triplicates. Relative expression of the tested genes
was calculated and normalized using the 2−ΔΔCtFigure 7 miR-211 reduces EOC tumorigenesis in vivo. A. Nude
mice were implanted with OVCAR3 cells stably expressing miR-Ctrl or
miR-211. Tumor volume was measured every five days. B. Tumor weight
determined at day 25. *p < 0.05, **p < 0.01 compared to LV-miR-Ctrl
transfected cells. Data are presented as mean ± SEM. C. Representative
images of formed tumors. D. Immunohistochemistry of Cyclin D1 and
CDK6 staining in LV-miR-Ctrl and LV-miR-211 groups.method. Primers were as follows: Cyclin D1 forward,
5′ GAGACCATCCCCCTGACGGC 3′, reverse, 5′ TCT
TCCTCCTCCTCGGCGGC 3′; CDK6 forward, 5′ CGA
ATGCGTGGCGGAGATC 3′, reverse, 5′ CCACTGAGG
TTAGAGCCATC 3′; β-actin forward, 5′ TGACGGGGT
CACCCACACTGTGCCCATCTA3′, reverse, 5′ CTAGA
AGCATTTGCGGTGGACGATGGAGGG 3′.
miRNA, lentivirus production, plasmid and transfection
Oligonucleotides including miR-211 miRNA, mimics
and non-specific miRNA negative control (miR-Ctrl)
[53] were synthesized and purified by GenePharma
(Shanghai). All oligonucleotides were transfected into
EOC cells at a final concentration of 50 nM using
HiPerFect transfection reagent according to the prod-
uct manual (Qiagen). The human miR-211 precursor
sequences were cloned into the lentivirus based ex-
pression plasmid pSILK (Addgene, Cambridge, MA).
Lentiviruses were packaged by transfecting HEK293T
cells with the lentivirus vector pSLIK, packing plasmid
psPAX2 and envelop plasmid pMD2.G (Addgene) in a
4:2:1 ratio using Lipofectamine 2000 (Invitrogen).
After 48 hours, the medium containing the lentiviruses
was collected. OVCAR3 cells were transduced with
1 × 106 IFU/ml of lentiviruses in 8 μg/ml of polybrene
(Sigma) for 16 hours. Forty-eight hours later, 150 μg/ml
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fected with the lentivirus. The full-length 3′UTR of
Cyclin D1 and CDK6 gene containing the putative
miR-211 biding sites was amplified by PCR and was
inserted into the pGL3 vector subcloned with CMV
promoter (Promega, Madison, WI). The coding se-
quences of Cyclin D1 and CDK6 were generated by
PCR and cloned into pCDNA3.1(+) vector (Invitrogen)
to generate pCDNA3.1-Cyclin D1 and pCDNA3.1-
CDK6. Correct insertion of PCR-amplified sequences
was confirmed by sequencing. The plasmid was trans-
fected using Lipofectamine LTX according to the man-
ufacturer’s instructions.
Cell counting and 3-(4, 5-dimethylthiazolyl-2-yl)-2-5
diphenyl tetrazolium bromide (MTT) assay
The cell viability and proliferation were determined by
cell counting and MTT assay (Promega). For cell count-
ing, at 48 hours after transfection, 0.25 × 104 cells were
seeded into 24-well plates. Then cells were trypsinized
and counted at 0, 1, 2, 3 and 4 days. For MTT assay,
2000 cells per well in a final volume of 100 μl were
plated in 96-well plates 48 hours after transfection. Then
at 0, 1, 2, 3 and 4 days, 25 μl of MTT stock solution was
added to each well and incubated for 4 hours. The ab-
sorbance was measured at 570 nm. The assays were per-
formed in triplicates.
Colony formation assay
Forty-eight hours after infection with LV-miR-Ctrl or
LV-miR-211, the EOC cells were seeded in 6-well plates
(500 cells per well) and incubated for 2 weeks for the
colony formation assay. The cells were then washed
with PBS, fixed with 10% formalin, and stained with
0.5% crystal violet (Sigma). The assay was repeated
in triplicates.
Cell cycle assay
Forty-eight hours after transfection with miRNA mimics,
EOC cells were seeded in 6-well plates. Two days later,
the cells were collected and fixed in 70% ethanol,
washed in PBS, re-suspended in 200 μl of PBS contain-
ing 0.5 mg/ml RNase, 0.05% Triton X-100 and 10 μg/ml
propidium iodide (Sigma), incubated for 1 hour at 37°C
in the dark, and analyzed immediately using a Flow
Cytometer (BD Biosciences, San Jose, CA). The ex-
periment was done in triplicates.
Luciferase reporter assay
The cells were seeded in triplicate in 24-well plates one
day before transfection for the luciferase assays. Plasmids
inserted into the Renilla lucifearse vector (Promega) with
Cyclin D1 or CDK6 3′UTR inserts were co-transfected
with miR-Ctrl or miR-211 plasmids. Forty eight hoursafter transfection, the cells were harvested and lysed,
and the luciferase activity assayed using the dual-
luciferase assay kit (Promega). Normalized luciferase ac-
tivity was reported as luciferase activity/Renilla lucif-
erase activity. Three independent experiments were
performed.
Western blot
Total protein was extracted using RIPA buffer (50 mM
Tris–HCl pH 7.4,150 mM NaCl, 1% NP-40, 1% sodium
deoxycholic acid, 0.1% SDS, 1 mM phenylmethylsulfonyl
fluoride, protease inhibitor cocktail; Santa Cruz, Santa
Cruz, CA). The total extracts were separated using 10%
SDS-polyacrylamide gels and electrophoretically trans-
ferred to polyvinylidene difluoride membranes (PVDF,
Bio-Rad, Hercules, CA). The membranes were probed
with a primary antibodies against human CDK6, Cyclin
D1 and β-actin (Santa Cruz), followed by HRP-
conjugated sencondary antibody (Santa Cruz). Bound
antibodies were detected using the Supersignal West
Pico ECL chemiluminescence kit (Thermo scientific,
Rockford, IL).
Animal studies
Animal studies were approved by the Institutional Ani-
mal Care and Use Committee of Harbin Medical Univer-
sity. Nude mice (5 weeks old) were randomly divided
into two groups (n = 8 per group). A suspension of
OVCAR3 cells (1 × 107) stably expressing miR-211 or
cells infected with miR-Ctrl were injected subcutane-
ously into the left flank of each group. Tumor volumes
were measured every 5 days using a caliper. Thirty days
after implantation, the mice were sacrificed and the sub-
cutaneous tumors excised and weighed.
Immunohistochemistry
Tumor samples were fixed in 4% formaldehyde, embed-
ded in paraffin wax, and then cut into 5 μm sections.
Samples were deparaffinized in clearite and rehydrated.
After blocking endogenous peroxidase and performing
antigen retrieval, tissue slides were blocked in goat
serum for 30 min and incubated with antibodies against
Cyclin D1 or CDK6 (1:100 dilution) overnight at 4°C,
followed by biotinylated secondary antibody (Santa
Cruz) for 30 min. Staining was performed in parallel
using a Vectastain ABC kit (Vector Laboratories).
Statistical analysis
The statistical analyses were performed using SPSS
Windows version 19. Data is expressed as mean ± SEM of
triplicate experiments. One-Way ANOVA was performed
to determine significant differences between groups. Differ-
ences were considered significant when p < 0.05 (*) and
highly significant when p < 0.01 (**).
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mutant B-C. Luciferase assay in OVCAR3 cells co-transfected with miR-211
and Cyclin D1 3′UTR wild type or Cyclin D1 3′UTR mutant plasmid.
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